View of Role of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitor Therapy in Treatment of Patients With Polycystic Ovary Syndrome: A Systemic Review of Metabolic and Cardiovascular Outcomes

Return to Issue Details Role of Proprotein Convertase Subtilisin Kexin Type 9 Inhibitor Therapy in Treatment of Patients With Polycystic Ovary Syndrome: A Systemic Review of Metabolic and Cardiovascular Outcomes Download Download PDF